Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

March 13, 2025

Study Completion Date

May 21, 2025

Conditions
Chronic Hepatitis b
Interventions
DRUG

AB-729

subcutaneous injection

DRUG

Peg-IFNα-2a

subcutaneous injection

Trial Locations (17)

2025

Arensia Exploratory Medicine Moldova, Chisinau

2747

Nepean Hospital, Kingswood

3065

St Vincent's Hospital Melbourne, Melbourne

33136

University of Miami Miller School of Medicine, Miami

48202

Henry Ford Health System, Detroit

49241

Pusan National University Hospital, Pusan

60002

Chia-Yi Christian Hospital, Chiayi City

83301

Chung-Ho Memorial Hospital, Kaohsiung City

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

85224

Arizona Liver Health, Chandler

85712

Arizona Liver Health, Tucson

92105

Research and Education, Inc., San Diego

08844

ID Care, Hillsborough

Unknown

Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

Queen Mary Hospital, Hong Kong

Asan Medical Center, Seoul

01135

Medical Center of Limited Liability Company Harmoniya Krasy, Kyiv

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY